<DOC>
	<DOCNO>NCT01500850</DOCNO>
	<brief_summary>The aim study observe change cardiovascular biomarkers treatment Lantus patient Type 2 Diabetes mellitus .</brief_summary>
	<brief_title>Establishing Cardiovascular Biomarkers Define Preferred Lantus® Use</brief_title>
	<detailed_description>- Phase IV - Indication : Diabetes mellitus Type 2 - Primary objective : To compare fast intact proinsulin secretion begin 24 week treatment period . - Secondary objective : To evaluate change parameter - insulin , - glucose , - intact proinsulin ( glucose challenge ) , - hsCRP , - adiponectin , - MMP-9 , - HbA1c , - weight 24 week treatment . To investigate change - glucose , - intact proinsulin , - hsCRP , - adiponectin , - HbA1c - weight visit 2 ( baseline ) , visit 6 ( 12 week ) visit 8 ( final visit 24 week ) . To investigate number patient normal value parameter hsCRP , adiponectin , intact proinsulin 24 week treatment ( responder rate ) . -Primary efficacy variable : Fasting intact proinsulin concentration timepoint Visit 2 ( Baseline ) Visit 8 ( 24 week treatment ) -Secondary efficacy variable : All secondary parameter assess 24 week treatment compare versus baseline assessment . - Weight - hsCRP - Adiponectin - MMP-9 - OGTT parameter ( insulin , intact proinsulin , glucose time point 0 , 60 120 minute 24 week - HOMA-IR score - HbA1c Additionally follow parameter assess visit 6 compare visit 2 visit 8 : - Weight - hsCRP - Adiponectin - Fasting intact Proinsulin - Glucose - HbA1c - Safety Variables : - Adverse Events - Hypoglycaemic event Medication/Dosage : Insulin glargine , dose individually adapted reach treatment goal ( FBG ≤ 100 mg/dL ) NPH Insulin , dose individually adapt reach treatment goal ( FBG ≤ 100 mg/dL ) Insulin glulisine , dose individually adapted reach treatment goal ( FBG ≤ 100 mg/dL ) Human Insulin , dose individually adapt reach treatment goal ( FBG ≤ 100 mg/dL ) -Study Duration : Duration study participation one patient approximately 26 week . Overall total duration study approximately 10 month . Design : This randomize four arm , open-label , multi-center study . Population Patients Type 2 Diabetes mellitus , Sample Size n = 60 ( 15 per arm )</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<criteria>Give write informed consent . Patient consent his/her family physician/diabetologist inform trial participation Type2 diabetes mellitus ≥ 1 year diagnosis ( male female ) Experienced self blood glucose measurement ≥ 3 month . HbA1c ≤ 9 % &gt; 6,5 % BMI &gt; 30 kg/m² Age ≥ 18 year Waist circumference &gt; 88 cm ( female ) &gt; 102 cm ( male ) NPH insulin treatment plus 1 2 OAD ( except TZD ) History drug alcohol abuse within last five year prior screen Anamnestic history hypersensitivity study drug ( component study drug ) drug similar chemical structure History severe multiple allergy Treatment investigational drug within 3 month prior screen Progressive fatal disease History significant cardiovascular , respiratory , gastrointestinal , hepatic ( ALAT and/or ASAT &gt; 3 time normal reference range ) , renal ( creatinine &gt; 1.3 mg/dl woman &gt; 1.6 mg/dl men ) , neurological , psychiatric and/or hematological disease judge investigator Pregnant lactate woman Sexually active woman childbearing potential consistently correctly practice birth control implant , injectables , combine oral contraceptive , hormonal intrauterine device ( IUDs ) , sexual abstinence vasectomize partner Treatment GLP1analog Thiazolidinediones ( TZD ) hsCRP &gt; 10 mg/l ( rapid test screen visit ) . Lack compliance similar reason , accord investigator , preclude satisfactory participation study Type 1 Diabetes mellitus Patients already treat intensified conventional insulin therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Type 2 Diabetes mellitus</keyword>
	<keyword>NPH insulin</keyword>
	<keyword>Insulin Glargine</keyword>
	<keyword>cardiovascular biomarkers</keyword>
	<keyword>hsCRP , adiponectin</keyword>
	<keyword>intact proinsulin</keyword>
	<keyword>cardiovascular risk</keyword>
</DOC>